Intervacc AB and Dechra Pharmaceuticals PLC enter into an Agreement to Commercialize Strangvac in Europe
Stockholm, April 12, 2021 - Intervacc AB (“Intervacc”) announced today that they have entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC, (“Dechra”) to commercialize Intervacc’s leading vaccine candidate Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. Strangvac is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. The distribution agreement is based